Suppr超能文献

恶性胶质瘤:谁能从辅助化疗中获益?

Malignant glioma: who benefits from adjuvant chemotherapy?

作者信息

DeAngelis L M, Burger P C, Green S B, Cairncross J G

机构信息

Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

出版信息

Ann Neurol. 1998 Oct;44(4):691-5. doi: 10.1002/ana.410440418.

Abstract

We combined two randomized prospective Brain Tumor Study Group data sets to analyze the effects of prognostic factors on survival by treatment group. Adjuvant chemotherapy increased long-term survival regardless of prognostic factors. Pathological review revealed that oligo dendrogliomas were overrepresented among long-term survivors independent of therapy. Prognostic factors do not predict benefit from adjuvant nitrosourea in malignant gliomas, and long-term survival with chemotherapy is not explained by oligodendroglial tumors.

摘要

我们合并了两个随机前瞻性脑肿瘤研究组的数据集,以按治疗组分析预后因素对生存的影响。无论预后因素如何,辅助化疗均可提高长期生存率。病理检查显示,少突胶质细胞瘤在长期存活者中所占比例过高,与治疗无关。预后因素无法预测恶性胶质瘤患者从辅助亚硝基脲治疗中是否获益,化疗后的长期生存也无法用少突胶质细胞瘤来解释。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验